ATE221915T1 - Identifizierung eines menschlichen rezeptor- tyrosinkinasegens - Google Patents

Identifizierung eines menschlichen rezeptor- tyrosinkinasegens

Info

Publication number
ATE221915T1
ATE221915T1 AT92907369T AT92907369T ATE221915T1 AT E221915 T1 ATE221915 T1 AT E221915T1 AT 92907369 T AT92907369 T AT 92907369T AT 92907369 T AT92907369 T AT 92907369T AT E221915 T1 ATE221915 T1 AT E221915T1
Authority
AT
Austria
Prior art keywords
receptor
receptor tyrosine
tyrosine kinase
identification
kinase gene
Prior art date
Application number
AT92907369T
Other languages
English (en)
Inventor
Bruce Israel Terman
Miguel Eduardo Carrion
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE221915T1 publication Critical patent/ATE221915T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AT92907369T 1991-02-22 1992-02-20 Identifizierung eines menschlichen rezeptor- tyrosinkinasegens ATE221915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65723691A 1991-02-22 1991-02-22
PCT/US1992/001300 WO1992014748A1 (en) 1991-02-22 1992-02-20 Identification of a novel human receptor tyrosine kinase gene

Publications (1)

Publication Number Publication Date
ATE221915T1 true ATE221915T1 (de) 2002-08-15

Family

ID=24636385

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907369T ATE221915T1 (de) 1991-02-22 1992-02-20 Identifizierung eines menschlichen rezeptor- tyrosinkinasegens

Country Status (8)

Country Link
EP (1) EP0536350B1 (de)
AT (1) ATE221915T1 (de)
CA (1) CA2083401C (de)
DE (1) DE69232718T2 (de)
DK (1) DK0536350T3 (de)
ES (1) ES2180535T3 (de)
SG (1) SG49753A1 (de)
WO (1) WO1992014748A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
JPH07504813A (ja) * 1992-01-22 1995-06-01 ニユー・イングランド・デイーコネス・ホスピタル 新規蛋白質チロシンキナーゼ類
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
KR100335584B1 (ko) * 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6872699B2 (en) 1992-11-13 2005-03-29 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JP3734262B2 (ja) * 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
CA2175893C (en) 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
JP3944241B2 (ja) * 1995-12-18 2007-07-11 スージェン・インコーポレーテッド Ａｕｒ―１および／またはａｕｒ―２関連疾患の診断および処置
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
JP4405597B2 (ja) 1997-06-18 2010-01-27 メルク エンド カムパニー インコーポレーテッド ヒト受容体型チロシンキナーゼｋｄｒ
JP4841724B2 (ja) 1998-10-09 2011-12-21 ベジェニクス ピーティーワイ リミテッド 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
EP1579871A1 (de) 1998-12-22 2005-09-28 Genentech, Inc. Antagonisten von vaskular-endothelialen Zellwachstumsfaktoren und ihre Anwendung
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1179541B1 (de) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
KR20020059609A (ko) 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
EP2377555A3 (de) 2004-11-18 2011-11-23 Imclone LLC Antikörper gegen den vaskulären endothelialen Wachstumsfaktorrezeptor-1
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof

Also Published As

Publication number Publication date
DE69232718T2 (de) 2003-04-03
EP0536350A1 (de) 1993-04-14
WO1992014748A1 (en) 1992-09-03
SG49753A1 (en) 1998-06-15
ES2180535T3 (es) 2003-02-16
EP0536350A4 (de) 1994-03-22
CA2083401C (en) 2003-03-25
DK0536350T3 (da) 2002-09-02
CA2083401A1 (en) 1992-08-23
EP0536350B1 (de) 2002-08-07
DE69232718D1 (de) 2002-09-12

Similar Documents

Publication Publication Date Title
DE69232718D1 (de) Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
Huang et al. Chemotactic factor induced tyrosine phosphorylation of membrane associated proteins in rabbit peritoneal neutrophils
EA199800116A1 (ru) Пирролопиримидины и фармацевтические композиции, включающие эти соединения
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
BR0009721A (pt) Inibidores de tirosina quinase de proteìna cìclica
IL191078A0 (en) POLYPEPTIDES WHICH BIND TO ErbB3 OR ErbB4 RECEPTOR PROTEIN TYROSINE KINASE OR BOTH, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS, METHOD FOR PRODUCTION AND USE OF SUCH POLYPEPTIDES
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
ATE324441T1 (de) Htk-ligand
FI972492L (fi) Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
CA2079585A1 (en) Ligand for the neu gene product
DK0418797T3 (da) Pyrimidin-4,6-dicarboxylsyrediamider, fremgangsmåde til deres fremstilling, deres anvendelse samt lægemiddel på basis af disse forbindelser
NO961845L (no) Drikk og en fremgangsmåte for å fremstille den
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
BR0016624A (pt) Abrilhantadores óticos anfotéricos, suas soluções aquosas, sua produção e seu uso
DE69129034D1 (de) Molekulare klone von hiv-1 und deren verwendung
DE69535901D1 (de) Proteinkinase npk-110
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
ATE110074T1 (de) Quinolyloxazol-2-one, nützlich als proteinkinase- c-inhibitoren.
BR9916216A (pt) 4.5-azolo-oxindóis
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
ATE271125T1 (de) Neuartige tyrosinkinase
EA199900256A1 (ru) Нуклеотидная и белковая последовательность маммастатина и способы применения
Watanabe et al. Expression of C-terminal src kinase in human colorectal cancer cell lines
ATE262584T1 (de) Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0536350

Country of ref document: EP

REN Ceased due to non-payment of the annual fee